HRP20171476T1 - Pripravak koji sadrži nikotin i opipramol te upotreba istog - Google Patents
Pripravak koji sadrži nikotin i opipramol te upotreba istog Download PDFInfo
- Publication number
- HRP20171476T1 HRP20171476T1 HRP20171476TT HRP20171476T HRP20171476T1 HR P20171476 T1 HRP20171476 T1 HR P20171476T1 HR P20171476T T HRP20171476T T HR P20171476TT HR P20171476 T HRP20171476 T HR P20171476T HR P20171476 T1 HRP20171476 T1 HR P20171476T1
- Authority
- HR
- Croatia
- Prior art keywords
- nicotine
- pharmaceutically acceptable
- opipramol
- disease
- pharmaceutical preparation
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims 11
- YNZFUWZUGRBMHL-UHFFFAOYSA-N 2-[4-[3-(11-benzo[b][1]benzazepinyl)propyl]-1-piperazinyl]ethanol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 title claims 11
- 229960002715 nicotine Drugs 0.000 title claims 11
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims 11
- 229960005290 opipramol Drugs 0.000 title claims 11
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 7
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 6
- 239000000181 nicotinic agonist Substances 0.000 claims 6
- 210000003169 central nervous system Anatomy 0.000 claims 5
- 238000000586 desensitisation Methods 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 210000001428 peripheral nervous system Anatomy 0.000 claims 5
- 208000030507 AIDS Diseases 0.000 claims 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 4
- 238000002360 preparation method Methods 0.000 claims 4
- 230000005586 smoking cessation Effects 0.000 claims 4
- 206010057852 Nicotine dependence Diseases 0.000 claims 3
- 208000025569 Tobacco Use disease Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 208000018726 traumatic encephalopathy Diseases 0.000 claims 2
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 229940112822 chewing gum Drugs 0.000 claims 1
- 235000015218 chewing gum Nutrition 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (19)
1. Farmaceutski pripravak koji sadrži nikotinski agonist i inhibitor desenzitacije nikotinskog acetilkolinskog receptora (nAChR), te farmaceutski prihvatljivog nosioca, naznačeno time da je nikotinski agonist nikotin ili farmaceutski prihvatljiva sol, ili N-oksid iste; te da je inhibitor desenzitacije nAChR-a opipramol ili farmaceutski prihvatljiva sol ili ester iste.
2. Farmaceutski pripravak prema zahtjevu 1, naznačeno time da je nikotinski agonist nikotin, a inhibitor desenzitacije nAChR-a opipramol.
3. Farmaceutski pripravak prema zahtjevu 1 ili 2, naznačeno time da su nikotinski agonist i nAChR-a prisutni u težinskom omjeru od otprilike 1:2 do 1:100, poželjno 1:5 do 1:20, poželjnije 1:14, gdje je prva stavka nikotinski agonist, a druga stavka inhibitor desenzitacije nAChR-a.
4. Farmaceutski pripravak prema bilo kojem zahtjevu od 1 do 3, naznačeno time da je spomenuti pripravak prikladan za oralnu, parenteralnu, transkutanu, mukoznu, transdermalnu ili inhalacijsku primjenu, a poželjno je u obliku žvakaće gume, tankog listića, vrećice, transdermalnog flastera, kapsule, tablete, ili nazalnog spreja.
5. Farmaceutski pripravak prema zahtjevu 4, koji je transdermalni flaster koji sadrži nikotin i opipramol ili farmaceutski prihvatljivu sol ili ester iste, te farmaceutski prihvatljivog nosioca prikladnog za transdermalnu ili topikalnu primjenu.
6. Farmaceutski pripravak prema zahtjevu 5, naznačeno time da je transdermalni flaster izrađen kako bi osigurao značajno kontinuiranu isporuku nikotina ili opipramola pacijentu.
7. Farmaceutski pripravak prema bilo kojem zahtjevu od 1 do 6, namijenjen isporuci sa kontroliranim otpuštanjem nikotinskog agonista i inihibitora desenzitacije nAChR-a u predodređenim intervalima isporuke, naznačeno time da su spomenuti predodređeni vremenski intervali isporuke poželjno značajno kontinuirani kroz barem 1 dan.
8. Farmaceutski pripravak kontroliranog otpusta prema zahtjevu 7, koji sadrži nikotin i opipramol ili farmaceutski prihvatljivu sol ili ester iste.
9. Farmaceutski pripravak prema bilo kojem zahtjevu od 1 do 8, za upotrebu u liječenju bolesti, poremećaja ili stanja središnjeg živčanog susatava (CNS) ili perifernog živčanog sustava (PNS), ili za upotrebu radi induciranja prestanka pušenja.
10. Upotreba farmaceutskog pripravka prema zahtjevu 9, naznačeno time da je spomenuta bolest, poremećaj ili stanje CNS ili PNS-a, izabrana između kognitivnog poremećaja, Alzheimerove bolesti, Parkinsonove bolesti, anksioznosti, depresije, shizofrenije, poremećaja hiperaktivnosti (ADHD), poremećaja deficita pažnje (ADD), vaskularne demencije, Lewy body demencije, post-traumatske demencije, Pickove bolesti, multiple skleroze, Jakob-Creutzfeldtove bolesti, ovisnosti o nikotinu, ovisnosti o alkoholu, ovisnosti o kanabisu, neuroloških stanja povezanih sa sindromom stečene imunodeficijencije (AIDS) ili Huntingtonove bolesti.
11. Farmaceutski pripravak prema bilo kojem zahtjevu 1 do 8, kod upotrebe za liječenje ili supresije duhanske ili nikotinske ovisnosti ili upotrebe iste za induciranje prestanka pušenja.
12. Oprema koja obuhvaća farmaceutski pripravak koji sadrži nikotin ili farmaceutski prihvatljivu sol, ili N-oksid iste, farmaceutski pripravak koji sadrži opipramol ili farmaceutski prihvatljivu sol ili ester iste, te upute za primjenu spomenutih pripravaka za liječenje bolesti, poremećaja ili stanja CNS ili PNS-a ili za upotrebu pri induciranju prestanka pušenja, za upotrebu pri liječenju bolesti, poremećaja ili stanja CNS ili PNS-a ili za upotrebu pri induciranju prestanka pušenja.
13. Oprema za upotrebu prema zahtjevu 12, naznačeno time da svaki farmaceutski pripravak je u obliku transdermalnog flastera.
14. Oprema za upotrebu prema zahtjevu 13, koja sadrži prvi flaster koji sadrži nikotin i drugi flaster koji sadrži opipramol ili farmaceutski prihvatljivu sol ili ester iste.
15. Oprema za upotrebu prema zahtjevu 14, koja sadrži prvi flaster koji sadrži nikotin i drugi flaster koji sadrži opipramol ili farmaceutski prihvatljivu sol ili ester iste, te farmaceutski prihvatljivog nosioca za transdermalnu ili topikalnu primjenu.
16. Oprema za upotrebu prema zahtjevu 15, naznačeno time da je transdermalni flaster izrađen kako bi osigurao značajno kontinuiranu isporuku nikotina ili opipramola.
17. Oprema za upotrebu prema bilo kojem zahtjevu 12 do 16, naznačeno time da je spomenuti poremećaj CNS-a izabran između kognitivnog poremećaja, Alzheimerove bolesti, Parkinsonove bolesti, anksioznosti, depresije, shizofrenije, poremećaja hiperaktivnosti (ADHD), poremećaja deficita pažnje (ADD), vaskularne demencije, Lewy body demencije, post-traumatske demencije, Pickove bolesti, multiple skleroze, Jakob-Creutzfeldtove bolesti, ovisnosti o nikotinu, ovisnosti o alkoholu, ovisnosti o kanabisu, neuroloških stanja povezanih sa sindromom stečene imunodeficijencije (AIDS) ili Huntingtonove bolesti.
18. Medicinski uređaj za kontrolirano otpuštanje koji sadrži pripravak koji sadrži nikotin ili opipramol ili farmaceutski prihvatljivu sol ili ester iste; koji je u mogućnosti otpuštati pripravak u predodređenim rintervalima isporuke pacijentu.
19. Medicinski uređaj za kontrolirano otpuštanje prema zahtjevu 18, naznačeno time da su preodređeni inervali isporuke značajno kontinuirani kroz barem 1 dan.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99016107P | 2007-11-26 | 2007-11-26 | |
| EP08855517.2A EP2224917B1 (en) | 2007-11-26 | 2008-11-26 | Composition comprising nicotine and opipramol and use thereof |
| PCT/IL2008/001546 WO2009069126A1 (en) | 2007-11-26 | 2008-11-26 | Compositions comprising nicotinic agonists and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171476T1 true HRP20171476T1 (hr) | 2017-12-15 |
Family
ID=40380297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171476TT HRP20171476T1 (hr) | 2007-11-26 | 2017-10-04 | Pripravak koji sadrži nikotin i opipramol te upotreba istog |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8273731B2 (hr) |
| EP (1) | EP2224917B1 (hr) |
| JP (1) | JP5456687B2 (hr) |
| KR (1) | KR101613742B1 (hr) |
| CN (1) | CN101925352B (hr) |
| AR (1) | AR069752A1 (hr) |
| AU (1) | AU2008331102B2 (hr) |
| BR (1) | BRPI0819911A2 (hr) |
| CA (1) | CA2744736C (hr) |
| CL (1) | CL2008003507A1 (hr) |
| CY (1) | CY1119768T1 (hr) |
| DK (1) | DK2224917T3 (hr) |
| ES (1) | ES2642873T3 (hr) |
| HR (1) | HRP20171476T1 (hr) |
| HU (1) | HUE035105T2 (hr) |
| LT (1) | LT2224917T (hr) |
| MX (1) | MX2010005804A (hr) |
| PL (1) | PL2224917T3 (hr) |
| PT (1) | PT2224917T (hr) |
| SI (1) | SI2224917T1 (hr) |
| WO (1) | WO2009069126A1 (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008003507A1 (es) * | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
| WO2010014760A1 (en) | 2008-08-01 | 2010-02-04 | Zoran Corporation | Video encoder with an integrated temporal filter for denoising |
| US9801865B2 (en) * | 2008-09-24 | 2017-10-31 | The United States Of America As Represented By The Department Of Veteran Affairs | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
| US8529914B2 (en) * | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| ES2605814T3 (es) | 2011-04-29 | 2017-03-16 | Moberg Pharma Ab | Composiciones farmacéuticas que comprenden un anestésico local tal como bupivacaína para administración local en la boca o la garganta |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| BR112016021034A8 (pt) | 2014-03-13 | 2021-06-29 | Neuroderm Ltd | composição farmacêutica, uso da mesma e kit |
| US20170216273A1 (en) * | 2014-05-29 | 2017-08-03 | Jory F. Goodman | Nicotine Derivatives and Methods of Use |
| WO2016042413A1 (en) * | 2014-09-18 | 2016-03-24 | Neuroderm, Ltd. | Opipramol patch |
| US9597284B2 (en) | 2014-10-20 | 2017-03-21 | Oyster Point Pharma, Inc. | Dry eye treatments |
| MX2017007042A (es) | 2014-12-05 | 2018-06-15 | Juul Labs Inc | Control de dosis calibrada. |
| CN114432313A (zh) | 2016-04-07 | 2022-05-06 | 奥伊斯特普安生物制药公司 | 治疗眼部病状的方法 |
| US10292977B2 (en) * | 2016-04-11 | 2019-05-21 | Neurocea, LLC | Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases |
| US10639300B2 (en) * | 2016-04-12 | 2020-05-05 | Arturo Solis Herrera | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
| WO2018097629A1 (ko) * | 2016-11-24 | 2018-05-31 | 에스케이케미칼 주식회사 | 바레니클린 서방성 제제 및 이의 제조 방법 |
| WO2018150276A2 (en) | 2017-02-16 | 2018-08-23 | Universidad San Sebastian | The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions |
| US20200000822A1 (en) * | 2017-02-23 | 2020-01-02 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| US10961296B2 (en) * | 2017-11-10 | 2021-03-30 | Howard Hughes Medical Institute | Modified ligand-gated ion channels and methods of use |
| LU101519B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5069094A (en) * | 1987-09-08 | 1991-12-03 | Birkestrand Orville J | Tube end finishing machine |
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5336675A (en) * | 1991-05-14 | 1994-08-09 | Ernir Snorrason | Method of treating mania in humans |
| WO1993023045A1 (en) * | 1992-05-18 | 1993-11-25 | Pharmaco Behavioral Associates, Inc. | Use of cotinine to alleviate tobacco withdrawal syndrome |
| JPH09262287A (ja) * | 1996-03-28 | 1997-10-07 | Terumo Corp | 薬液注入装置 |
| WO1998009523A1 (en) * | 1996-09-05 | 1998-03-12 | Massachusetts Institute Of Technology | Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| ATE355854T1 (de) * | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
| US6479076B2 (en) * | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
| DE10134038A1 (de) | 2001-07-12 | 2003-02-06 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit |
| US20030119879A1 (en) | 2001-10-15 | 2003-06-26 | Thomas Landh | Nicotine and chocolate compositions |
| US6852741B2 (en) * | 2001-12-31 | 2005-02-08 | University Of Florida | Compositions and methods for treatment of neurological disorders |
| US7045534B2 (en) * | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
| DK1587506T3 (da) * | 2002-12-18 | 2008-11-24 | Algorx | Administration af capsaicinoider |
| ITMI20030828A1 (it) | 2003-04-18 | 2004-10-19 | Farchemia Srl | Procedimento per la preparazione dell'opipramolo. |
| PL1670433T3 (pl) * | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
| EP1763337A2 (en) * | 2003-12-31 | 2007-03-21 | Actavis Group HF | Immediate, controlled and sustained release formulations of galanthamine |
| US20050234024A1 (en) * | 2004-04-14 | 2005-10-20 | Clarke David E | Materials and methods for the treatment of ulcerative colitis |
| WO2005115471A2 (en) | 2004-05-27 | 2005-12-08 | Neurocure Ltd. | Methods and compositions for treatment of nicotine dependence and dementias |
| US20060142349A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
| US20080014252A1 (en) * | 2006-07-14 | 2008-01-17 | Delprete Keith | Topical compositions with long lasting effect |
| WO2008011484A2 (en) | 2006-07-18 | 2008-01-24 | Bethesda Pharmacology Associates, Llc | Nicotinic desensitizers and methods of selecting, testing, and using them |
| WO2008028903A2 (en) * | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| CL2008003507A1 (es) | 2007-11-26 | 2009-11-27 | Neuroderm Ltd | Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico. |
-
2008
- 2008-11-25 CL CL2008003507A patent/CL2008003507A1/es unknown
- 2008-11-26 ES ES08855517.2T patent/ES2642873T3/es active Active
- 2008-11-26 DK DK08855517.2T patent/DK2224917T3/en active
- 2008-11-26 HU HUE08855517A patent/HUE035105T2/en unknown
- 2008-11-26 EP EP08855517.2A patent/EP2224917B1/en not_active Not-in-force
- 2008-11-26 PL PL08855517T patent/PL2224917T3/pl unknown
- 2008-11-26 JP JP2010534598A patent/JP5456687B2/ja not_active Expired - Fee Related
- 2008-11-26 CA CA2744736A patent/CA2744736C/en not_active Expired - Fee Related
- 2008-11-26 LT LTEP08855517.2T patent/LT2224917T/lt unknown
- 2008-11-26 CN CN200880126096.9A patent/CN101925352B/zh not_active Expired - Fee Related
- 2008-11-26 WO PCT/IL2008/001546 patent/WO2009069126A1/en active Application Filing
- 2008-11-26 AU AU2008331102A patent/AU2008331102B2/en not_active Ceased
- 2008-11-26 PT PT88555172T patent/PT2224917T/pt unknown
- 2008-11-26 MX MX2010005804A patent/MX2010005804A/es active IP Right Grant
- 2008-11-26 BR BRPI0819911A patent/BRPI0819911A2/pt not_active IP Right Cessation
- 2008-11-26 AR ARP080105141A patent/AR069752A1/es not_active Application Discontinuation
- 2008-11-26 SI SI200831872T patent/SI2224917T1/sl unknown
- 2008-11-26 US US12/323,779 patent/US8273731B2/en not_active Expired - Fee Related
- 2008-11-26 KR KR1020107014088A patent/KR101613742B1/ko not_active IP Right Cessation
-
2012
- 2012-08-24 US US13/593,911 patent/US8921356B2/en not_active Expired - Fee Related
-
2014
- 2014-11-26 US US14/554,660 patent/US20150306109A1/en not_active Abandoned
-
2016
- 2016-09-08 US US15/259,752 patent/US20170128432A1/en not_active Abandoned
-
2017
- 2017-10-04 HR HRP20171476TT patent/HRP20171476T1/hr unknown
- 2017-10-04 CY CY20171101027T patent/CY1119768T1/el unknown
- 2017-11-30 US US15/827,293 patent/US20180303818A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5456687B2 (ja) | 2014-04-02 |
| BRPI0819911A2 (pt) | 2017-06-13 |
| CA2744736C (en) | 2015-06-09 |
| KR101613742B1 (ko) | 2016-04-19 |
| US8273731B2 (en) | 2012-09-25 |
| LT2224917T (lt) | 2017-12-27 |
| EP2224917B1 (en) | 2017-07-05 |
| CL2008003507A1 (es) | 2009-11-27 |
| WO2009069126A1 (en) | 2009-06-04 |
| AR069752A1 (es) | 2010-02-17 |
| AU2008331102B2 (en) | 2014-04-10 |
| CN101925352B (zh) | 2016-03-16 |
| MX2010005804A (es) | 2010-11-30 |
| AU2008331102A1 (en) | 2009-06-04 |
| US20150306109A1 (en) | 2015-10-29 |
| HUE035105T2 (en) | 2018-05-02 |
| ES2642873T3 (es) | 2017-11-20 |
| US8921356B2 (en) | 2014-12-30 |
| CY1119768T1 (el) | 2018-06-27 |
| DK2224917T3 (en) | 2017-10-16 |
| EP2224917A1 (en) | 2010-09-08 |
| PT2224917T (pt) | 2017-10-17 |
| KR20100105841A (ko) | 2010-09-30 |
| US20090149446A1 (en) | 2009-06-11 |
| PL2224917T3 (pl) | 2018-02-28 |
| JP2011504490A (ja) | 2011-02-10 |
| CA2744736A1 (en) | 2009-06-04 |
| US20130172321A1 (en) | 2013-07-04 |
| SI2224917T1 (sl) | 2017-12-29 |
| US20170128432A1 (en) | 2017-05-11 |
| CN101925352A (zh) | 2010-12-22 |
| US20180303818A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171476T1 (hr) | Pripravak koji sadrži nikotin i opipramol te upotreba istog | |
| JP2011504490A5 (hr) | ||
| US11478449B1 (en) | Compositions of matter and pharmaceutical compositions | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| JP2011517654A5 (hr) | ||
| WO2009047173A3 (de) | Zerstäuber | |
| MX354423B (es) | Formulaciones de rasagilina de liberación prolongada y usos de las mismas. | |
| IL215910A (en) | Derivatives 4,2,1 - Triazolo [3,4 – a] Pyridine, pharmaceutical preparations contain them and processes for their preparation and their uses for the preparation of drugs for the treatment of diseases of the central nervous system | |
| Mazurov et al. | 2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands | |
| JP2007526256A5 (hr) | ||
| WO2008108517A3 (en) | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same | |
| JP2013518914A5 (hr) | ||
| JP2015524423A5 (hr) | ||
| JP2007505139A5 (hr) | ||
| JP2016512490A5 (hr) | ||
| Islam et al. | Improved treatment of nicotine addiction and emerging pulmonary drug delivery | |
| JP2011500819A5 (hr) | ||
| AU2002354856B2 (en) | Active substance combination for medicamentous therapy of nicotine dependency | |
| MY141724A (en) | Medicaments containing betamimetic drugs and a novel anticholinesterase drug | |
| WO2008062453B1 (en) | Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form | |
| Smith | Legalising medical cannabis in Australia. | |
| EP4164746A1 (en) | Method for treating or mitigating parkinson's disease using nicotine inhaler or nicotine nasal spray | |
| Hughes et al. | Can-aDaPPT SummaRy STaTEmEnTS FOR PhaRmaCOThERaPy | |
| JP2008519016A5 (hr) | ||
| Niaura et al. | FRESH FROM THE PIPELINE |